Our vision is to create value by forming clusters of companies around a defined medical condition which in principle enable knowledge synergies thus enhancing innovation in research and commercial realization.
Our approach is to facilitate interactions between our cluster's companies, broadening the exposure to new ideas and approaches, promoting discussion forums amongst researchers and officers, challenging management teams and attracting top-level expertise. Furthermore, this modus operando leads to cost savings from economies of scale, shared best practices and specified expertise that result in better overall performance and a wider exposure to key opinion leaders, Pharmaceutical and Medical companies, investors and other relevant institutions.
Key benefits to cluster portfolio companies include:
Interaction with other researchers and officers focused on the same medical condition which facilitate knowledge synergies and triggers innovation
Shared best practices and expertise generating better performance
Access to superior managerial guidance and knowhow
Access to greater market understanding
Better exposure to key opinion leaders, investors and institutions
Operational synergies and other cost savings due to scaling up.
Key benefits to BioLight include:
A broader scope of innovation generated by each cluster of companies in the given disease segment
Accumulated value resulting from enhanced innovation (“1+1>2”)
A balanced investment portfolio - within clusters and between clusters - mitigating risk
Attractive opportunities for strategic collaborations, investments and improved ROI
Attractive deal flow
Attractive and empowering structure to attract investors and investments
